REVAXIS is a 3-in-1 booster vaccine that helps protect against three separate diseases: diphtheria, tetanus and poliomyelitis (polio).
REVAXIS Prescribing information
REVAXIS helps boost protection against diphtheria, tetanus and polio in a single injection. Revaxis is given as part of the national immunisation programme to teenagers at around 14 years of age (school year 9), providing the fifth and final routine vaccine against tetanus, diphtheria and polio.
|
|
Presentation |
Schedule |
Further doses |
Age range |
|
Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) |
0.5 ml prefilled syringe Available in 1 syringe packs |
1 dose |
Revaxis® may be used as a booster following primary immunisation with inactivated or oral poliomyelitis vaccines Revaxis® is indicated as a booster following primary vaccination. Revaxis® is not intended for primary immunisation |
6 years + |
Before you prescribe this vaccine please refer to the Prescribing information and SmPC links below.
Sanofi Pasteur is committed to providing you and your patients with a comprehensive range of support materials, including disease awareness patient leaflets and in-surgery display items.
• Simply visit https://sanofi.medisa.com
• Select the user group which best describes your role in your organisation
• Narrow your search by selecting the appropriate disease area
• Select which materials you would like to receive and how many
• Log-in or register to create an account
• Confirm your order
MAT-GB-2003198(v1.0) | October 2020
